Evogliptin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Evogliptin
Evogliptin.svg
Clinical data
Trade namesSuganon
Other namesDA-1229
Routes of
administration
By mouth
ATC code
Identifiers
  • (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-{[(2-methyl-2-propanyl)oxy]methyl}-2-piperazinone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H26F3N3O3
Molar mass401.430 g·mol−1
3D model (JSmol)
  • CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](Cc2cc(c(cc2F)F)F)N
  • InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
  • Key:LCDDAGSJHKEABN-MLGOLLRUSA-N

Evogliptin (INN; trade name Suganon) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.[1] It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea.[2]

References[edit]

  1. ^ McCormack PL (November 2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–9. doi:10.1007/s40265-015-0496-5. PMID 26541763.
  2. ^ "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015.